ライフサイエンスコーパス: cilengitide

1 ned clinical subgroups showed a benefit from cilengitide.

2 For patients treated at cilengitide 2,400 mg/m(2), the 6-month cumulative incide

3 receive temozolomide chemoradiotherapy with cilengitide 2000 mg intravenously twice weekly (cilengit

4 ality RIT (CMRIT) using RIT and six doses of Cilengitide (250 microg/dose; n = 41).

5 Cilengitide alone did not alter tumor growth when compar

6 Integrin beta3 antagonist, cilengitide, also enhanced tumor growth and increased M2

7 t other integrin subunits, or treatment with cilengitide, an Arg-Gly-Asp (RGD) mimetic, impaired HSV-

8 Cilengitide, an inhibitor of alphavbeta3 and alphavbeta5

9 ll migration and proliferation compared with cilengitide, an integrin-targeting peptidomimetic that p

10 In conclusion, CMRIT, combining Cilengitide and RIT, significantly increased the efficac

11 o, we show that coadministration of low-dose Cilengitide and Verapamil increases tumor angiogenesis,

12 Cilengitide (CGT) is a cyclic pentapeptide that demonstr

13 We aimed to assess cilengitide combined with temozolomide chemoradiotherapy

14 ning was performed on the cyclic RGD-peptide Cilengitide, cyclo[R-G-D-f-N(Me)V] 1, and its parent pep

15 etermine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perf

16 phase I trial of the antiangiogenesis agent cilengitide (EMD 121974), an alpha v beta 3,5 integrin a

17 her, and how, the cyclic Arg-Gly-Asp peptide Cilengitide (EMD 121974), which targets the alpha(v)beta

18 al was 26.3 months (95% CI 23.8-28.8) in the cilengitide group and 26.3 months (23.9-34.7) in the con

19 population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thr

20 engitide 2000 mg intravenously twice weekly (cilengitide group) or temozolomide chemoradiotherapy alo

21 The phase II dosage of intravenous cilengitide in children with refractory brain tumors is

22 ucted to evaluate the activity and safety of cilengitide in GBM patients at first recurrence.

23 ase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 count

24 Thus, the dual action of low-dose Cilengitide, in vessels and tumor cells, improves chemot

25 compared with untreated mice, but CMRIT with Cilengitide increased efficacy of treatment, with the cu

26 Additional studies integrating cilengitide into combinatorial regimens for GBM are warr

27 Cilengitide is a selective alphavbeta3 and alphavbeta5 i

28 Cilengitide is well tolerated to doses of 2,400 mg/m2, d

29 imaging system, we report that a new (125)I-Cilengitide-like RGD-cyclopentapeptide, containing d-mor

30 Cilengitide monotherapy is well tolerated and exhibits m

31 moter, and 545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oc

32 ay 21, began a 2-week treatment with SC-080, cilengitide, or the EGFR inhibitor PKI166.

33 soluble RGD ligands, such as osteopontin or cilengitide, promoted association of Rab-coupling protei

34 s pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy f

35 in clinical and preclinical use (SC-080 and cilengitide, respectively) mediates SMC apoptosis and re

36 Lower-dose RIT (200 mu Ci) combined with Cilengitide resulted in less increase in cures (36 compa

37 stin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Trea

38 ed Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Trea

39 A phase II trial to assess the efficacy of cilengitide therapy for children with refractory brain t

40 The addition of cilengitide to temozolomide chemoradiotherapy did not im

41 No vehicle- or cilengitide-treated animal survived beyond 2 weeks.

42 d between groups of untreated mice (n = 24), Cilengitide-treated mice (n = 18), RIT (200-260 mu Ci (9

43 ted no overall additional toxic effects with cilengitide treatment.

44 ssigned to receive either 500 or 2,000 mg of cilengitide twice weekly on a continuous basis.

45 Patients received cilengitide twice weekly on a continuous basis.

46 The safety profile of cilengitide was excellent, with no significant reproduci

47 zolomide was given for up to six cycles, and cilengitide was given for up to 18 months or until disea

48 No increased toxicity attributable to Cilengitide was observed based upon pooled blood sample

49 the RGD sequence of the cyclic pentapeptide cilengitide when bound to integrin alpha(V)beta(3).

50 chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticanc